Ocugen Total Current Assets vs Deferred Long Term Liab Analysis
OCGN Stock | USD 0.91 0.01 1.11% |
Ocugen financial indicator trend analysis is much more than just breaking down Ocugen Inc prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ocugen Inc is a good investment. Please check the relationship between Ocugen Total Current Assets and its Deferred Long Term Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocugen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
Total Current Assets vs Deferred Long Term Liab
Total Current Assets vs Deferred Long Term Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ocugen Inc Total Current Assets account and Deferred Long Term Liab. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Ocugen's Total Current Assets and Deferred Long Term Liab is -0.32. Overlapping area represents the amount of variation of Total Current Assets that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Ocugen Inc, assuming nothing else is changed. The correlation between historical values of Ocugen's Total Current Assets and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Assets of Ocugen Inc are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Total Current Assets i.e., Ocugen's Total Current Assets and Deferred Long Term Liab go up and down completely randomly.
Correlation Coefficient | -0.32 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Total Current Assets
The total value of all assets that are expected to be converted into cash within one year or during the normal operating cycle.Deferred Long Term Liab
Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.Most indicators from Ocugen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ocugen Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocugen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. At this time, Ocugen's Selling General Administrative is very stable compared to the past year. Tax Provision is expected to grow at the current pace this year, while Issuance Of Capital Stock is likely to drop about 19.8 M.
Ocugen fundamental ratios Correlations
Click cells to compare fundamentals
Ocugen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ocugen fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 16.8M | 27.4M | 105.8M | 108.6M | 64.5M | 48.2M | |
Other Current Liab | 206.0K | 2.9M | 4.0M | 8.3M | 2.2M | 2.4M | |
Total Current Liabilities | 4.5M | 3.6M | 7M | 18.5M | 17.1M | 17.9M | |
Total Stockholder Equity | 11.0M | 21.6M | 95.8M | 84.1M | 40.6M | 22.2M | |
Property Plant And Equipment Net | 222.5K | 633.0K | 1.2M | 6.1M | 17.3M | 18.2M | |
Net Debt | (6.0M) | (21.5M) | (91.7M) | (71.2M) | (32.5M) | (34.1M) | |
Retained Earnings | (51.5M) | (73.3M) | (131.7M) | (213.0M) | (286.2M) | (271.9M) | |
Accounts Payable | 1.9M | 395K | 2.3M | 8.1M | 3.2M | 2.8M | |
Cash | 7.4M | 24.0M | 95.0M | 77.6M | 39.5M | 37.6M | |
Non Current Assets Total | 1.0M | 1.5M | 3.1M | 10.1M | 21.6M | 22.7M | |
Non Currrent Assets Other | 667.7K | 714.5K | 1.8M | 3.1M | 4.3M | 4.5M | |
Cash And Short Term Investments | 7.4M | 24.0M | 95.0M | 90.9M | 39.5M | 38.9M | |
Common Stock Total Equity | 513K | 527.5K | 1.8M | 2.0M | 2.3M | 2.4M | |
Common Stock Shares Outstanding | 13.9M | 112.2M | 195.0M | 214.6M | 244.3M | 256.5M | |
Liabilities And Stockholders Equity | 16.8M | 27.4M | 105.8M | 108.6M | 64.5M | 48.2M | |
Non Current Liabilities Total | 1.2M | 2.2M | 2.9M | 6.1M | 6.9M | 13.1M | |
Other Current Assets | 8.3B | 1.8M | 15.4M | 7.6M | 3.5M | 3.3M | |
Other Stockholder Equity | 62.0M | (1.7B) | 225.5M | 294.8M | 324.1M | 340.4M | |
Total Liab | 5.8M | 5.8M | 9.9M | 24.6M | 24.0M | 18.9M | |
Property Plant And Equipment Gross | 222.5K | 633.0K | 1.5M | 6.7M | 18.5M | 19.4M | |
Total Current Assets | 15.8M | 25.9M | 102.6M | 98.5M | 43.0M | 42.0M | |
Accumulated Other Comprehensive Income | (10.9M) | (10.3M) | 0.0 | 26K | 20K | 21K | |
Common Stock | 527.5K | 1.8M | 2.0M | 2.2M | 2.6M | 2.7M | |
Short Long Term Debt Total | 1.4M | 2.5M | 3.3M | 6.4M | 6.9M | 7.3M | |
Current Deferred Revenue | 2.3M | 2.9M | 4.0M | 11.2M | 10.5M | 5.6M | |
Other Assets | 474.2K | 432.1K | 2.0M | 177K | 203.6K | 193.4K | |
Long Term Debt | 1.1M | 1.8M | 1.7M | 2.3M | 2.8M | 1.5M | |
Capital Surpluse | 215.9M | 62.0M | 93.1M | 225.5M | 203.0M | 137.0M | |
Short Term Debt | 172.3K | 278K | 726K | 996K | 1.1M | 1.5M | |
Property Plant Equipment | 222.5K | 1.1M | 1.2M | 10.0M | 11.5M | 12.0M | |
Net Tangible Assets | 11.0M | 21.6M | 95.8M | 84.1M | 96.7M | 101.5M | |
Net Invested Capital | 12.1M | 23.6M | 97.5M | 86.3M | 43.4M | 39.5M | |
Net Working Capital | 11.2M | 22.3M | 95.6M | 80.0M | 25.9M | 39.7M |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Ocugen Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ocugen. If investors know Ocugen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ocugen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.19) | Revenue Per Share 0.018 | Quarterly Revenue Growth 1.353 | Return On Assets (0.48) | Return On Equity (1.03) |
The market value of Ocugen Inc is measured differently than its book value, which is the value of Ocugen that is recorded on the company's balance sheet. Investors also form their own opinion of Ocugen's value that differs from its market value or its book value, called intrinsic value, which is Ocugen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ocugen's market value can be influenced by many factors that don't directly affect Ocugen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ocugen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ocugen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ocugen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.